ArticleThe Journal of infectious diseases2015
Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.
Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 148 citations in OpenAlex.
- Comparison of Ebola virus infection routes and resulting disease in animal models.Journal of virology · 2026Review
- A Single-Dose Bundibugyo Virus Vaccine Protects Macaques Within 3 Days.bioRxiv : the preprint server for biology · 2026Article
- Differences in cynomolgus macaque populations used for infectious disease research.Animal models and experimental medicine · 2026Review
- Ebola virus matrix protein VP40 triggers inflammatory responses linked to the ebolavirus virulence.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- A review of post-exposure strategies for high-consequence viral pathogens in the laboratory.Clinical microbiology reviews · 2025Review
- Fast-acting single-dose vesicular stomatitis virus-Sudan virus vaccine: a challenge study in macaques.The Lancet. Microbe · 2025Article
- A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease.Emerging microbes & infections · 2025Article
- Filovirus infection disrupts epithelial barrier function and ion transport in human iPSC-derived gut organoids.PLoS pathogens · 2025Article
- Characterization of Ravn virus viral shedding dynamics in experimentally infected Egyptian rousette bats (Journal of virology · 2025Article
- Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus.Nature communications · 2025Article
- Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates.Nature medicine · 2025Article
- Single-dose VSV-Sudan virus vaccine protects from lethal Sudan virus infection within one week: a challenge study in macaques: VSV-SUDV but not VSV-EBOV protects NHPs from Sudan virus disease.bioRxiv : the preprint server for biology · 2025Article
- The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection.Science advances · 2025Article
- Article
- Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model.Viruses · 2025Article
- Evaluating Countermeasures Against Marburg Virus Using a Mouse Model.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Single-cycle, pseudotyped reporter influenza virus to facilitate evaluation of treatment strategies for avian influenza, Ebola and other highly infectious diseasesFrontiers in immunology · 2025Article
- Evaluation of Vaccines and Therapeutics Against Marburg Virus in Nonhuman Primate Models.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Evaluation of Vaccines and Therapeutics Against Ebolaviruses in the Domestic Ferret.Methods in molecular biology (Clifton, N.J.) · 2025Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
The filoviruses, Ebola virus and Marburg virus, are zoonotic pathogens that cause severe hemorrhagic fever in humans and nonhuman primates (NHPs), with case-fatality rates ranging from 23% to 90%. The current outbreak of Ebola virus infection in West Africa, with >26 000 cases, demonstrates the long-underestimated public health danger that filoviruses pose as natural human pathogens. Currently, there are no vaccines or treatments licensed for human use. Licensure of any medical countermeasure may require demonstration of efficacy in the gold standard cynomolgus or rhesus macaque models of filovirus infection. Substantial progress has been made over the last decade in characterizing the filovirus NHP models. However, there is considerable debate over a variety of experimental conditions, including differences among filovirus isolates used, routes and doses of exposure, and euthanasia criteria, all of which may contribute to variability of results among different laboratories. As an example of the importance of understanding these differences, recent data with Ebola virus shows that an addition of a single uridine residue in the glycoprotein gene at the editing site attenuates the virus. Here, we draw on decades of experience working with filovirus-infected NHPs to provide a perspective on the importance of various experimental conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.